Shares of Capricor Therapeutics surged by 70% on Friday following the company’s announcement that the U.S. Food and Drug Administration (FDA) is willing to review new data regarding its experimental Duchenne muscular dystrophy drug, deramiocel. This development offers a critical lifeline to the company’s regulatory prospects after a major setback last month.
Key Developments
-
FDA Re-engagement: The regulator has agreed to review an upcoming submission of new data, signaling a potential pivot in the review process. This move is viewed by market analysts as a “potentially positive surprise,” as it suggests the agency is actively evaluating a path forward rather than simply rejecting the application.
-
Focus on New Evidence: Capricor plans to submit an amendment featuring new 24-month clinical data. Unlike previous submissions that faced scrutiny regarding heart function metrics, this new data will focus on improvements in upper limb muscle function, an area where some advisory panel members previously expressed receptiveness.
-
Timeline Extension: The FDA is expected to treat this as a “major amendment,” which would likely extend the review timeline by approximately three months.
-
Operational Prudence: While the stock saw a sharp recovery, it remains well below its pre-setback levels. The company has announced it is pacing its commercial launch spending to maintain a conservative financial position while awaiting final regulatory clarity.
Market Context
-
Previous Setback: In July, the company’s prospects were severely impacted after an FDA advisory panel voted 9-3 against the existing effectiveness data. Panel members and FDA staff had raised concerns over the consistency of the trial’s outcome measures and the patient cohort’s baseline cardiac health.
-
Analyst Sentiment: Market watchers are cautiously optimistic. Investment firms like Oppenheimer have noted that the regulator’s willingness to review new data supports an “upside case” for potential approval.
